Recent trading activity in Corcept Therapeutics options indicates a growing anticipation of volatility surrounding the company's future. Investors are utilizing a long strangle strategy, which involves buying both call and put options to capitalize on potential price swings.
This strategy reflects market sentiment that significant developments may unfold as the company approaches key milestones in 2027. Such events could include regulatory approvals or major product launches, which typically drive stock price fluctuations.
As traders position themselves for these potential changes, the options market is signaling that they expect notable movements in Corcept's stock price in the coming years. Investors are closely monitoring the situation as they weigh their strategies.